Orforglipron vs Tirzepatide

Orforglipron is an experimental oral pill for type 2 diabetes and obesity that works by activating the GLP-1 pathway, while Tirzepatide is an injectable drug already on the market (sold as Mounjaro for diabetes and Zepbound for obesity) that targets both GLP-1 and GIP pathways. Tirzepatide is FDA-approved to treat type 2 diabetes, obesity, and obstructive sleep apnea, whereas Orforglipron has no approved uses yet. The main practical difference is that Orforglipron is taken by mouth and still in development, while Tirzepatide is given as a shot and is available now.

AI summary of the sources below.